The short version of thymalfasin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-19. Anything still debated is marked as such rather than presented as settled.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
==== Egypt ==== Egypt approved Viagra for sale in 2002, but soon afterwards allowed local companies to produce generic versions of the drug, citing the interests of poor people who would not be able to afford Pfizer's price.
== Further reading == Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, et al. (August 2016). "Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials". Clin Pharmacokinet. 55 (8): 907–23. doi:10.1007/s40262-015-0364-1. PMC 5680399. PMID 26798032.
=== Hydrothermal self-assembly === Graphene has been prepared by using a sugar like glucose, fructose, etc. This substrate-free "bottom-up" synthesis is safer, simpler and more environmentally friendly than exfoliation. The method can control the thickness, ranging from monolayer to multilayer, which is known as the "Tang-Lau Method".
Sources: en.wikipedia.org
Generation Z's top career choices—becoming business people, doctors, engineers, artists, and IT workers—are not that different from generations past. For them, the most important qualities in a job are income, fulfillment, work-life balance, and job security. In particular, Generation Z prioritizes a work-life balance more than older cohorts and are highly interested in flexible work schedules. Millennials and Generation Z (74%) tend to have more colleagues working remotely for a significant portion of their time compared to the Baby Boomers (58%). Most members of Generation Z prefer to work for a medium or large company rather than a startup or a government agency. Access to the Internet has made self-employment much easier than it was in the past; indeed, by the mid-2010s, a majority of Generation Z were running their own businesses instead of holding "traditional" teen jobs, such as waiting tables. Morgan Stanley reported in 2019 that Millennials and Generation Z have been responsible for a surge in labor participation in the United States, and that while the American workforce was expanding, other G10 countries faced a shrinking number of workers. This development alleviates concerns over America's aging population which jeopardizes the solvency of various welfare programs. As of 2019, Millennials and Generation Z accounted for 38% of the American workforce, a number that is projected to rise to 58% in the incoming decade.
== Entry == The Clinical School was established in 1976 while construction of the new building at its present site was underway. The clinical course was restructured in 2005 with the addition of a new final year, as the clinical course had previously been less than three years in length. Before 2017, approximately half of medical students left Cambridge after the pre-clinical course as there were not enough places on the clinical course for them all; common destinations included medical schools based in Oxford, London and Manchester. From 2017, all medical students continue to study in Cambridge for the full six years provided they pass the pre-clinical component of the course. Students enter the clinical course at Cambridge following satisfactory progression during the pre-clinical component of the combined medical course or as part of the graduate course.
== Research and career == Barran stayed with Stace for three years after completing her PhD in 1998. In 2001 Barran joined the University of California, Santa Barbara, working as a postdoctoral fellow with Mike Bowers. She was interested in the structure and stability of small molecules in the gas phase. She looked at how Ion-mobility spectrometry could be used to identify conformation. Barran joined the University of Edinburgh as an Engineering and Physical Sciences Research Council (EPSRC) Advanced Research Fellow in 2002. In 2005 she was awarded the 10th Desty Memorial prize for her innovations in Separation Science. She was made a Senior Lecturer in 2009. She worked on mass spectrometry techniques that can be used to evaluate conformational change, aggregation and intrinsic conformation. She investigated mass spectrometry for therapeutics for pre-fibrillar aggregation. She helped to establish the Scottish Instrumentation and Resource Centre for Advanced Mass Spectrometry at the University of Edinburgh. This had an initial remit to provide proteomic analysis for the MRC Human Genetics Unit. In 2013 Barran was appointed to the Manchester Institute of Biotechnology as a Chair in Mass Spectrometry sponsored by Waters Corporation. She led an EPSRC platform grant to study the structure-activity relationships of Beta defensins. She works with Cait MacPhee, Garth Cooper and Tilo Kunath on neurodegenerative proteins, and with several groups including Richard Kriwacki, Rohit Pappu and Gary Daughdrill to examine intrinsically disordered proteins.
=== Continuous and individualized delivery systems === As Parkinson's disease advances, the duration, efficacy and reliability of levodopa progressively decline producing unstable plasma concentration and motor fluctuations. The fluctuations contribute to a series of motor and non-motor complications including wearing off and levodopa induced dyskinesia that need a better tailored pharmaceutical approach to the disease. A steady activation of the dopaminergic receptors was initially pursued through intravenous infusion which shortly was replaced by a series of new levodopa device-aided formulations. Duodopa or Levodopa-carbidopa intestinal gel (LCIG) is a methylcellulose-based suspension of levodopa and carbidopa delivered in a continuous way into the duodenum or jejunum through a portable pump and a PEG-J tube system. In randomized studies, LCIG proved to reduce daily OFF time and increase ON time without troublesome dyskinesia but, at the same time, carries with it problems related to the infusion system, such as PEG-J and stoma complications. Produodopa is a soluble prodrug formulation of fosfolevodopa/foscarbidopa developed for a 24 hour subcutaneous infusion. After the infusion, the prodrug is converted by phosphatases into active levodopa and carbidopa that manage to stabilize their concentration in the blood. Compared with levodopa/carbidopa, the prodrug approach increases ON time without troublesome dyskinesia by 1.75 hours and reduced OFF time by 1.79 hours other than improvements also in quality of life, motor fluctuations and sleep.
Sources: en.wikipedia.org
=== Box office === In North America, Stone Cold opened on 1729 screens through TriStar Pictures on May 17, 1991. It debuted in fifth place, drawing $2.8 million in its first weekend, and quickly fell off the charts, ending its run with a disappointing $9.2 million at the domestic box office. In the U.K., the movie was also distributed by Columbia TriStar and opened on June 19, 1992, only reaching eighth place. It perhaps fared best in Germany, where it was a minor success for independent distributor Ascot Elite, drawing 781,000 admissions in a medium-wide release and spending four weeks in the nation's top ten.
== Further reading == Wainwright, Dylan K.; Lauder, George V. (2017). "Mucus Matters: The Slippery and Complex Surfaces of Fish" (PDF). In Gorb, Stanislav N.; Gorb, Elena V. (eds.). Functional Surfaces in Biology III: Diversity of the Physical Phenomena. Biologically-Inspired Systems. Vol. 10. Springer, Cham. pp. 223–246. doi:10.1007/978-3-319-74144-4_10. ISBN 978-3-319-74144-4. Retrieved 2021-09-13.
Human Growth Hormone Fragment 176–191 (hGH frag 176–191) is a peptide fragment of human growth hormone. It has erroneously been presented as a lipolytic peptide fragment based on extrapolations of clinical data pertaining to AOD9604, a modified form of hGH frag 176–191. In contrast to AOD9604, hGH frag 176–191 has not been studied in humans.
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.